Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
120.4 USD | -0.07% | -2.97% | -2.10% |
Financials (USD)
Sales 2024 * | 4.1B | Sales 2025 * | 4.39B | Capitalization | 7.51B |
---|---|---|---|---|---|
Net income 2024 * | 481M | Net income 2025 * | 649M | EV / Sales 2024 * | 2.57 x |
Net Debt 2024 * | 3B | Net Debt 2025 * | 1.61B | EV / Sales 2025 * | 2.08 x |
P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
12.3
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.18% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | -0.07% | ||
1 week | -2.97% | ||
Current month | +1.28% | ||
1 month | -7.15% | ||
3 months | -2.38% | ||
6 months | -8.10% | ||
Current year | -2.10% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 13 M€ | -.--% | ||
14.47% | 227 M€ | +6.28% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 120.4 | -0.07% | 409,944 |
24-03-27 | 120.5 | +2.19% | 471,653 |
24-03-26 | 117.9 | -2.37% | 1,689,780 |
24-03-25 | 120.8 | -0.84% | 597,609 |
24-03-22 | 121.8 | -1.85% | 691,817 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.10% | 7.51B | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |